JP2004507251A - 癌の治療効果を増強するための方法 - Google Patents

癌の治療効果を増強するための方法 Download PDF

Info

Publication number
JP2004507251A
JP2004507251A JP2002522514A JP2002522514A JP2004507251A JP 2004507251 A JP2004507251 A JP 2004507251A JP 2002522514 A JP2002522514 A JP 2002522514A JP 2002522514 A JP2002522514 A JP 2002522514A JP 2004507251 A JP2004507251 A JP 2004507251A
Authority
JP
Japan
Prior art keywords
antibody
tumor
cells
wnt
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002522514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004507251A5 (https=
Inventor
タイス，デイビッド
ペニカ，ダイアン
ポラキス，ポール
シェト，ウェイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/759,056 external-priority patent/US7173115B2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2004507251A publication Critical patent/JP2004507251A/ja
Publication of JP2004507251A5 publication Critical patent/JP2004507251A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
JP2002522514A 2000-08-29 2001-07-10 癌の治療効果を増強するための方法 Pending JP2004507251A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22891400P 2000-08-29 2000-08-29
US09/759,056 US7173115B2 (en) 2000-01-13 2001-01-11 Stra6 polypeptides
PCT/US2001/021635 WO2002018608A2 (en) 2000-08-29 2001-07-10 Methods for enhancing the efficacy of cancer therapy
US09/901,812 US20020173461A1 (en) 2000-01-13 2001-07-10 Methods for enhancing the efficacy of cancer therapy

Publications (2)

Publication Number Publication Date
JP2004507251A true JP2004507251A (ja) 2004-03-11
JP2004507251A5 JP2004507251A5 (https=) 2008-10-02

Family

ID=27397886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002522514A Pending JP2004507251A (ja) 2000-08-29 2001-07-10 癌の治療効果を増強するための方法

Country Status (10)

Country Link
EP (2) EP1341923A2 (https=)
JP (1) JP2004507251A (https=)
KR (1) KR20080068147A (https=)
AT (1) ATE453718T1 (https=)
AU (1) AU2001271938A1 (https=)
CA (1) CA2420867C (https=)
DE (1) DE60140966D1 (https=)
ES (1) ES2337696T3 (https=)
NZ (1) NZ524230A (https=)
WO (1) WO2002018608A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525041A (ja) * 2004-12-22 2008-07-17 ジェネンテック・インコーポレーテッド 可溶性多膜貫通型タンパク質の産生方法
JP2013224311A (ja) * 2007-03-30 2013-10-31 Nitto Denko Corp がん細胞および癌随伴線維芽細胞への標的化剤

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004519250A (ja) * 2000-03-23 2004-07-02 キュラゲン　コーポレイション 新規ヒトｓｔｒａ６様タンパク質およびこれをコードする核酸
CA2481239A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
SI2710035T1 (sl) 2011-05-16 2017-07-31 F. Hoffmann-La Roche Ag Agonisti FGFR1 in tehnike njihove uporabe
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
CN114574378B (zh) * 2022-04-11 2023-09-22 浙江大学 一种生产视黄酸的基因工程菌及其构建方法和应用
CN117625626B (zh) * 2024-01-25 2024-04-16 中国农业科学院植物保护研究所 RNAi在提高苏云金芽胞杆菌杀虫蛋白防治二化螟或草地贪夜蛾效果中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519491A (ja) * 2000-01-13 2003-06-24 ジェネンテック・インコーポレーテッド 新規なｓｔｒａ６ポリペプチド

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997852A (en) * 1987-08-26 1991-03-05 Ohio State University Research Foundation Method and composition for achieving cancer chemopreventive and chemotherapeutic activity
US5731167A (en) * 1992-01-17 1998-03-24 The United States Of America As Represented By The Department Of Health And Human Services Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519491A (ja) * 2000-01-13 2003-06-24 ジェネンテック・インコーポレーテッド 新規なｓｔｒａ６ポリペプチド

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525041A (ja) * 2004-12-22 2008-07-17 ジェネンテック・インコーポレーテッド 可溶性多膜貫通型タンパク質の産生方法
US8323902B2 (en) 2004-12-22 2012-12-04 Genentech, Inc. Methods for producing soluble membrane-spanning proteins
JP2013224311A (ja) * 2007-03-30 2013-10-31 Nitto Denko Corp がん細胞および癌随伴線維芽細胞への標的化剤
JP2015134789A (ja) * 2007-03-30 2015-07-27 日東電工株式会社 がん細胞および癌随伴線維芽細胞への標的化剤

Also Published As

Publication number Publication date
WO2002018608A3 (en) 2003-06-26
WO2002018608A9 (en) 2003-08-07
KR20080068147A (ko) 2008-07-22
WO2002018608A2 (en) 2002-03-07
CA2420867C (en) 2013-02-05
CA2420867A1 (en) 2002-03-07
EP1341923A2 (en) 2003-09-10
EP1666600B1 (en) 2009-12-30
EP1666600A1 (en) 2006-06-07
AU2001271938A1 (en) 2002-03-13
ES2337696T3 (es) 2010-04-28
DE60140966D1 (de) 2010-02-11
ATE453718T1 (de) 2010-01-15
NZ524230A (en) 2006-05-26

Similar Documents

Publication Publication Date Title
JP5701624B2 (ja) 新規なｓｔｒａ６ポリペプチド
ES2279473T3 (es) Procedimiento de diagnosis de tumores.
JP4260778B2 (ja) 腫瘍の治療のための組成物と方法
US20050176104A1 (en) Compositions and methods for the treatment of tumor
JP2009039097A (ja) 腫瘍治療のための組成物及び方法
JP2003519491A5 (https=)
JP2005531491A (ja) 癌の治療のための組成物と方法
JP2006519774A (ja) 癌の治療のための組成物と方法
KR20010103576A (ko) 종양 치료용 조성물 및 치료 방법
EP1666600B1 (en) Methods for enhancing the efficacy of cancer therapy
JP2003524390A (ja) 腫瘍治療のための組成物及び方法
KR100865801B1 (ko) 암 치료의 효능을 증진시키는 방법
AU2007203291B2 (en) Methods for enhancing the efficacy of cancer therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110817

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110916

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111024

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120313